Percutaneous Mitral Valve Procedures

Author(s):  
Sheela Pai Cole

As the population ages, more patients are presenting with symptomatic mitral valve disease that requires risk-prohibitive cardiac surgery. In the last decade, advances in valve technology have generated valves that can be inserted via a minimally invasive percutaneous approach. Nonetheless, patients must fulfill specific criteria in order to be considered for a percutaneous mitral intervention. From an anesthesiologist’s perspective, these cases are unique as they require both a detailed understanding of complex patient physiology and the need to be planned as fast-track procedures. Echocardiography is the cornerstone to success for these procedures, and typically a separate team of echocardiographers may be involved in the conduct of the case. This review discusses patient selection, complications of the procedure, and perioperative considerations for this technique.

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Yi Chen ◽  
Ling-chen Huang ◽  
Dao-zhong Chen ◽  
Liang-wan Chen ◽  
Zi-he Zheng ◽  
...  

Abstract Introduction Totally endoscopic technique has been widely used in cardiac surgery, and minimally invasive totally endoscopic mitral valve surgery has been developed as an alternative to median sternotomy for many patients with mitral valve disease. In this study, we describe our experience about a modified minimally invasive totally endoscopic mitral valve surgery and reported the preliminary results of totally endoscopic mitral valve surgery. The aim of this retrospective study is to evaluate the results of totally endoscopic technique in mitral valve surgery. Material and methods We retrospectively reviewed the profiles of 188 patients who were treated for mitral valve disease by modified totally endoscopic mitral valve surgery at our institution between January 2019 and December 2020. The procedure was performed under endoscopic right minithoracotomy and with femoro-femoral cannulation using the single two-stage venous cannula. Results A total of 188 patients underwent total endoscopic mitral valve surgery. Fifty-six patients had concomitant tricuspid valvuloplasty, 11 patients underwent concomitant ablation of atrial fibrillation and atrial septal defect repair was performed in three patients. Only one patient postoperatively died of multi-organ failure. Two patients were converted to median sternotomy. Except for one patient underwent operation to stop the bleeding from the incision site, no other serious complications nor reintervention occurred during the follow-up period. Conclusions The modified totally endoscopic mitral valve surgery performed at our institution is technically feasible and safe with the same efficacy as reported studies.


2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
T Viana ◽  
R M Vieira De Melo ◽  
D N V Da Silva ◽  
G P Santana ◽  
M L N De Paula ◽  
...  

Abstract Introduction Observational studies differ on the impact of performing tricuspid repair on surgical mortality. Some studies demonstrate increased surgical mortality related to right ventricular failure and circulatory shock, while there are other studies that evidence improvement in quality of life and signs of right heart failure in the long time. Objective To evaluate the impact on surgical mortality of concomitant tricuspid annuloplasty in patients undergoing cardiac surgery for rheumatic mitral valve disease, who have moderate to severe tricuspid regurgitation. Methods This is a prospective cohort from January 1, 2017 to December 30, 2020. All patients over 18 years of age who underwent cardiac surgery to correct rheumatic mitral valve disease with moderate to significant tricuspid regurgitation were included. The primary outcome was 30-days mortality. Results 165 patients were included, 98 (59.4%) underwent tricuspid valve annuloplasty. The mean age was 46, 5 (±12) years, the median of Euroscore II was 2,33%. The 30-days mortality was 17 (10.3%) and there was no difference between the groups submitted or not to tricuspid repair: 12 (12.2%) versus 5 (7.5%); p=0.44, respectively. In the multivariate analysis involving seven variables with a potential prediction of death in 30 days, tricuspid repair had no association with death, RR 2,4 (0,5 – 8,3); p=0.27. Conclusion In patients with rheumatic heart disease undergoing cardiac surgery for rheumatic mitral valve disease, perform tricuspid annuloplasty in individuals who had moderate to severe tricuspid insufficiency was not associated with increased surgical mortality. FUNDunding Acknowledgement Type of funding sources: None.


Author(s):  
O.Yu. Pidanov ◽  
K.V. Shcherbatyuk ◽  
N.A. Kolomeychenko ◽  
V.A. Tsepenshchikov

2003 ◽  
Vol 126 (2) ◽  
pp. 365-371 ◽  
Author(s):  
James P Greelish ◽  
Lawrence H Cohn ◽  
Marzia Leacche ◽  
Michael Mitchell ◽  
Alexandros Karavas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document